Jazz Pharmaceuticals to pay $20 million in penalties and compensation

Share this article:
Jazz Pharmaceuticals will pay $20 million in penalties and victim compensation to resolve criminal and civil investigations into illegal marketing by its Orphan Medical wholly owned subsidiary. The US Attorney for New York's Eastern District says Orphan pled guilty to felony misbranding for illegal promotion of Xyrem for unapproved uses.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions